Reticular Pseudodrusen A Risk Factor for Geographic Atrophy in Fellow Eyes of Individuals with Unilateral Choroidal Neovascularization

Grants

Funding Acknowledgements

Supported by the German Research Council (grant no.: DFG FI 1540/5-1 [R.P.F.]); the Perpetual Foundation Australia; Novartis Australia; Bayer Australia; the National Health and Medical Research Council Australia (grant nos.: 590205 and 1008979; practitioner fellowship no.: 529905 [R.H.G.]; and Centre for Clinical Research Excellence grant no.: 529923); the Macular Degeneration Foundation Australia (R.H.G. and G.S.H.); the BrightFocus Foundation, Clarksburg, MD; the National Institutes of Health, Bethesda, Maryland (grant no.: R24 EY017404 [G.S.H.]); the American Macular Degeneration Foundation, Inc, Northampton, MA; (G.S.H.); the Helen K. and Arthur E. Johnson Foundation, Denver, CO; (G.S.H.); the Willard L. Eccles Charitable Foundation, Salt Lake City, UT (G.S.H.); Sylvia E. Prahl-Brodbeck (G.S.H.); Sharon E. Steele-McGee; and Research to Prevent Blindness, Inc., New York, New York (unrestricted grant to the University of Utah John A. Moran Eye Center and the Department of Ophthalmology and Visual Sciences). The Centre for Eye Research Australia receives operational infrastructure support from the Victorian Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.